Cas no 77883-43-3 (Doxazosin mesylate)

Doxazosin mesylate is a selective α1-adrenergic receptor antagonist used in the management of benign prostatic hyperplasia (BPH) and hypertension. Its key advantages lie in its ability to relax smooth muscle, thereby improving urinary flow and reducing symptoms associated with BPH, while also offering a manageable blood pressure reduction profile.
Doxazosin mesylate structure
Doxazosin mesylate structure
Product Name:Doxazosin mesylate
CAS No:77883-43-3
MF:C24H29N5O8S
MW:547.580764532089
MDL:MFCD00216023
CID:59930
PubChem ID:135727074
Update Time:2025-11-10

Doxazosin mesylate Chemical and Physical Properties

Names and Identifiers

    • Doxazosin Mesylate
    • Doxazosin Mesilate
    • DOXAZOSIN MEYLATE
    • 1-(4-AMINO-6,7-DIMETHOXY-2-QUINAZOLINYL)-4-[4-(1,4-BENZODIOXAN-2-YL)CARPIPERAZIN-1-YL)]-6,7-DIMETHOXYQUINAZOLINE MESYLATE
    • 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl) piperazine methanesulfonate
    • CARDURA
    • CARDENALIN
    • DOXAZOSIN METHANESULFONATE
    • UK-33274-27
    • Doxazosin mesylate (Cardura? , Carduran?,Duracin?,Dosin? , Doxazocine?)
    • DOXAZOSIN MESYLATE, EP
    • UK 33274 mesylate
    • [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-3-yl)methanone,methanesulfonic acid
    • 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-[(1,4-benzodioxan-2-yl)carbonyl]piperazine Methanesulfonate
    • Carduran
    • Cardular
    • Cardura XL
    • Doxazomerck
    • Dedralen
    • Progandol
    • Diblocin
    • Tensiobas
    • Doxazosin AZU
    • Prostadilat
    • Tonocardin
    • Doxaben
    • Doksura
    • Kaltensif
    • Doxolbran
    • Cardoxan
    • Cardoral
    • Supressin
    • Normathen
    • Benur
    • Doxazosinmesylate
    • Diblocin Uro
    • Cardular Uro
    • Cardular PP
    • Diblocin PP
    • Doxazosin (mesylate)
    • Doxazosin mesylate [USAN]
    • MLS000028455
    • (4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl)(2,3-dih
    • SR-01000003045-2
    • DTXSID5045598
    • NSC-759284
    • HMS3714L17
    • NCGC00018158-09
    • DOXAZOSIN MESYLATE (USP MONOGRAPH)
    • CHEBI:4709
    • 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-((2,3-dihydro-1,4-benzodioxin-2-yl)ca rbonyl)piperazine
    • Alfadil
    • Z778141976
    • 2,3,4a,8a-tetrahydro-1,4-benzodioxin-3-yl-[4-(4-amino-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]methanone; methanesulfonate;Doxazosin mesylate
    • Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-((2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl)-, monomethanesulfonate
    • NCGC00016146-02
    • Mesylate, Doxazosin
    • DOXAZOSIN MESILATE [JAN]
    • Carduran Neo
    • DOXAZOSIN MESILATE [EP MONOGRAPH]
    • FT-0625592
    • HMS1570L17
    • DOXAZOSIN MESYLATE [USP-RS]
    • HSDB 7082
    • Tox21_500474
    • D4126
    • SMR000058441
    • (4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl)(2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methanonemethanesulfonate
    • Opera_ID_1881
    • DOXAZOSIN MESYLATE [USP MONOGRAPH]
    • piperazin-1-yl)(2,3-dihydrobenzo[b]
    • DOXAZOSIN MESYLATE (USP-RS)
    • DOXAZOSIN MESILATE [WHO-DD]
    • HMS3654J15
    • Doxazosin (as mesilate)
    • NCGC00093884-01
    • A839262
    • BCP12163
    • NS00076336
    • Doxazosin mesilate, European Pharmacopoeia (EP) Reference Standard
    • DOXAZOSIN MESILATE [MART.]
    • Tox21_110796
    • VJECBOKJABCYMF-UHFFFAOYSA-N
    • SR-01000003045-8
    • Dosin
    • 1 (4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-((2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl)piperazine
    • 4-amino-2-(4-(1,4-benzodioxan-2-carbonyl)-piperazin-1-yl)-6,7-dimethoxyquinazoli ne
    • KS-1052
    • SW197099-3
    • HMS2097L17
    • HMS3884O09
    • DOXAZOSIN MESYLATE [ORANGE BOOK]
    • BD164387
    • [1,4]dioxin-2-yl)methanone methanesulfonate
    • DOXAZOSIN MESILATE (EP MONOGRAPH)
    • CCG-213583
    • LP00474
    • Doxazosin mesylate, United States Pharmacopeia (USP) Reference Standard
    • AKOS015895371
    • 1-(4-AMINO-6,7-DIMETHOXY-2-QUINAZOLINYL)-4-(1,4-BENZODIOXAN-2-YLCARBONYL)PIPERAZINE METHANESULPHONATE
    • Q27106443
    • METHANONE, (4-(4-AMINO-6,7-DIMETHOXY-2-QUINAZOLINYL)-1-PIPERAZINYL)(2,3-DIHYDRO-1,4-BENZODIOXIN-2-YL)-, METHANESULFONATE (1:1)
    • NCGC00017136-01
    • Prestwick_1026
    • Tox21_110796_1
    • NSC 759284
    • HMS3372C03
    • SR-01000003045-4
    • CHEMBL1200561
    • MLS001148153
    • CAS-77883-43-3
    • 77883-43-3
    • EU-0100474
    • Doxazosin Mesylate,(S)
    • Doxazosin mesylate (USP)
    • CS-1830
    • Doxazosin mesylate [USAN:USP]
    • MLS000120399
    • MLS002222292
    • Duracin
    • 86P6PQK0MU
    • HMS3261O10
    • PIPERAZINE, 1-(4-AMINO-6,7-DIMETHOXY-2-QUINAZOLINYL)-4-((2,3-DIHYDRO-1,4-BENZODIOXIN-2-YL)CARBONYL)-, MONOMETHANESULPHONATE
    • NSC759284
    • MFCD00216023
    • D 9815
    • DTXCID3025598
    • DOXAZOSIN MESYLATE [VANDF]
    • CarduraXL
    • Doxazosin mesilate (JP17)
    • Doxazosin mesylate (USAN:USP)
    • MLS006011977
    • AC-6848
    • D00608
    • NCGC00261159-01
    • DOXAZOSIN MESYLATE [HSDB]
    • doxazosin mesylate salt
    • SR-01000003045
    • 4-Amino-2-[4-(1,4-benzodioxan-2-carbonyl)piperazin-1-yl]-6,7-dimethoxyquinazoline methanesulfonate
    • DOXAZOSIN MESYLATE [USP IMPURITY]
    • UNII-86P6PQK0MU
    • SCHEMBL42621
    • 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl)piperazine monomethanesulfonate
    • UK 33,274-27
    • Doxazocine
    • (4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl)(2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methanone methanesulfonate
    • 2-{4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]piperazin-1-yl}-6,7-dimethoxyquinazolin-4-amine; methanesulfonic acid
    • HMS2230L18
    • Cardura (TN)
    • DOXAZOSIN MESILATE (MART.)
    • C76492
    • UK 33274
    • s1324
    • UK-33,274-27
    • Pharmakon1600-01505976
    • HY-B0098A
    • Doxazosin mesylate, >=97% (HPLC), powder
    • HMS2093J14
    • DOXAZOSIN MESYLATE (USP IMPURITY)
    • Doxazosin mesylate
    • MDL： MFCD00216023
    • Inchi： 1S/C23H25N5O5.CH4O3S/c1-30-18-11-14-15(12-19(18)31-2)25-23(26-21(14)24)28-9-7-27(8-10-28)22(29)20-13-32-16-5-3-4-6-17(16)33-20;1-5(2,3)4/h3-6,11-12,20H,7-10,13H2,1-2H3,(H2,24,25,26);1H3,(H,2,3,4)
    • InChI Key： VJECBOKJABCYMF-UHFFFAOYSA-N
    • SMILES： S(C)(=O)(=O)O.O1C2C=CC=CC=2OCC1C(N1CCN(C2N=C(C3C=C(C(=CC=3N=2)OC)OC)N)CC1)=O
    • BRN： 7791129

Computed Properties

  • Exact Mass: 547.17400
  • Monoisotopic Mass: 547.174
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 2
  • Hydrogen Bond Acceptor Count: 12
  • Heavy Atom Count: 38
  • Rotatable Bond Count: 4
  • Complexity: 770
  • Covalently-Bonded Unit Count: 2
  • Defined Atom Stereocenter Count: 0
  • Undefined Atom Stereocenter Count : 1
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • Surface Charge: 0
  • Tautomer Count: 3
  • XLogP3: nothing
  • Topological Polar Surface Area: 175

Experimental Properties

  • Color/Form: White powder
  • Density: 1.371
  • Melting Point: 248-255°C
  • Boiling Point: 718°C at 760 mmHg
  • Flash Point: No data available
  • Solubility: biological extracorporealIn Vitro:DMSOsolubility33.33 mg/mL(60.87 mM;Need ultrasonic)H2O : 1 mg/mL(1.83 mM;Need ultrasonic)
  • Stability/Shelf Life: Protect from light
  • PSA: 175.02000
  • LogP: 2.88670
  • Solubility: Not determined
  • Vapor Pressure: No data available

Doxazosin mesylate Security Information

Doxazosin mesylate Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
SHANG HAI XIAN DING Biotechnology Co., Ltd.
D4126-100mg
Doxazosin mesylate
 77883-43-3 98.0%(LC&N)
100mg
 ￥405.0 2022-06-10
SHANG HAI XIAN DING Biotechnology Co., Ltd.
D4126-1g
Doxazosin mesylate
 77883-43-3 98.0%(LC&N)
1g
 ￥1475.0 2022-06-10
SHANG HAI MAI KE LIN SHENG HUA Technology Co., Ltd.
D837956-25g
Doxazosin Mesylate
 77883-43-3 ≥97 %
25g
 ￥4,180.00 2022-01-10
XI GE MA AO DE LI QI （ SHANG HAI ） MAO YI Co., Ltd.
Y0000553
Doxazosin mesylate
 77883-43-3 European Pharmacopoeia (EP) Reference Standard
￥2654.27 2022-02-23
XI GE MA AO DE LI QI （ SHANG HAI ） MAO YI Co., Ltd.
1225419-200MG
Doxazosin mesylate
 77883-43-3
200mg
 ￥3302.56 2025-01-11
TRC
D537500-50mg
Doxazosin Mesylate
 77883-43-3
50mg
 $ 57.00 2023-09-07
TRC
D537500-250mg
Doxazosin Mesylate
 77883-43-3
250mg
 $ 69.00 2023-09-07
TRC
D537500-500mg
Doxazosin Mesylate
 77883-43-3
500mg
 $97.00 2023-05-18
TRC
D537500-1g
Doxazosin Mesylate
 77883-43-3
1g
 $ 126.00 2023-09-07
TRC
D537500-2g
Doxazosin Mesylate
 77883-43-3
2g
 $242.00 2023-05-18

Doxazosin mesylate Suppliers

Suzhou Senfeida Chemical Co., Ltd
Gold Member
Audited Supplier Audited Supplier
(CAS:77883-43-3)Doxazosin mesylate
Order Number:sfd7522
Stock Status:in Stock
Quantity:200kg
Purity:99.9%
Pricing Information Last Updated:Friday, 19 July 2024 14:34
Price ($):discuss personally
Amadis Chemical Company Limited
Gold Member
Audited Supplier Audited Supplier
(CAS:77883-43-3)Doxazosin mesylate
Order Number:A839262
Stock Status:in Stock
Quantity:25g
Purity:99%
Pricing Information Last Updated:Friday, 30 August 2024 06:45
Price ($):298.0
Tiancheng Chemical (Jiangsu) Co., Ltd
Gold Member
Audited Supplier Audited Supplier
(CAS:77883-43-3)甲磺酸多沙唑嗪
Order Number:LE2755488
Stock Status:in Stock
Quantity:25KG,200KG,1000KG
Purity:99%
Pricing Information Last Updated:Friday, 20 June 2025 12:42
Price ($):discuss personally

Doxazosin mesylate Spectrogram

13C NMR
13C NMR
1H NMR 300 MHz DMSO
1H NMR

Doxazosin mesylate Related Literature

Related Categories

Additional information on Doxazosin mesylate

Professional Introduction to Doxazosin Mesylate (CAS No. 77883-43-3)

Doxazosin mesylate, a compound with the chemical name 1-(4-amino-6,7-dihydro-1-methyl-7-oxo-2-phenylpyrazolo[4,3-d]pyrimidin-5-yl)-4-(2,4-dichlorophenyl)piperazine monomethanesulfonate, is a well-known pharmaceutical agent widely recognized for its therapeutic applications. This compound, identified by its CAS number 77883-43-3, has garnered significant attention in the field of medicinal chemistry due to its unique pharmacological properties and mechanisms of action. Doxazosin mesylate is primarily utilized in the management of hypertension and BPH (benign prostatic hyperplasia), conditions that have seen considerable advancements in treatment modalities over recent years.

The pharmacological profile of doxazosin mesylate is characterized by its selective antagonism of alpha-adrenergic receptors. Specifically, it exhibits high affinity for alpha-1A receptors, which are predominantly found in the prostate, bladder neck, and other smooth muscle-rich tissues. This selective binding modulates the physiological processes mediated by norepinephrine and epinephrine, leading to vasodilation and relaxation of smooth muscles. Consequently, doxazosin mesylate effectively reduces symptoms associated with BPH by alleviating urinary obstruction and improving urinary flow rates. Similarly, its action on alpha-1 receptors in blood vessels contributes to the reduction of blood pressure in hypertensive patients.

Recent studies have delved into the molecular mechanisms underlying the therapeutic effects of doxazosin mesylate. Research indicates that this compound not only interacts with alpha-adrenergic receptors but also influences downstream signaling pathways involved in smooth muscle contraction and relaxation. For instance, studies have demonstrated that doxazosin mesylate can modulate the activity of K+ channels in smooth muscle cells, thereby contributing to its vasodilatory effects. These findings highlight the multifaceted pharmacological actions of doxazosin mesylate beyond mere receptor antagonism.

In addition to its established uses in hypertension and BPH, emerging research has explored potential applications of doxazosin mesylate in other therapeutic areas. Notably, preclinical studies have suggested that this compound may exhibit anti-inflammatory properties due to its ability to inhibit certain inflammatory pathways. The exact mechanisms remain under investigation, but preliminary data suggest that doxazosin mesylate could influence cytokine production and immune cell function. Such findings open up avenues for exploring its utility in conditions characterized by chronic inflammation.

The chemical structure of doxazosin mesylate also contributes to its pharmacological versatility. The presence of a piperazine ring and a phenyl moiety enhances its binding affinity to alpha-adrenergic receptors while minimizing off-target effects. Furthermore, the methanesulfonate salt form improves solubility and bioavailability, making it an effective drug candidate for oral administration. These structural features have been optimized through rigorous medicinal chemistry efforts to ensure maximal therapeutic efficacy and minimal adverse effects.

From a regulatory perspective, doxazosin mesylate has been thoroughly evaluated for safety and efficacy by global health authorities such as the FDA and EMA. Its approval for use in treating hypertension and BPH underscores its clinical significance and reliability. Regulatory agencies continue to monitor post-marketing surveillance data to ensure long-term safety profiles remain favorable. This ongoing evaluation process is crucial for maintaining high standards of patient care and ensuring that therapeutic agents like doxazosin mesylate remain effective over time.

The synthesis of doxazosin mesylate involves a multi-step process that requires precise control over reaction conditions to ensure high yield and purity. Key synthetic steps include condensation reactions between appropriate precursors followed by functional group transformations such as methylation and sulfonation. Advanced analytical techniques such as HPLC (high-performance liquid chromatography) and NMR (nuclear magnetic resonance) spectroscopy are employed throughout the synthesis process to monitor reaction progress and verify product integrity.

The manufacturing process adheres to stringent quality control measures to ensure consistency across batches. Good Manufacturing Practices (GMP) are rigorously followed to maintain high standards of product quality from raw material procurement to final formulation. This commitment to quality ensures that patients receive a reliable and effective therapeutic agent that meets regulatory requirements.

Economic considerations also play a significant role in the broader context of doxazosin mesylate production and distribution. The cost-effectiveness of this medication makes it an accessible option for patients worldwide who suffer from hypertension or BPH. Pharmaceutical companies continuously work towards optimizing production processes to reduce costs without compromising on quality or efficacy. Such efforts are essential for ensuring widespread availability of essential medicines like doxazosin mesylate.

The future prospects for doxazosin mesylate are promising, with ongoing research exploring novel applications beyond its current indications. For instance, studies are investigating its potential role in managing symptoms associated with neurodegenerative disorders due to its ability modulate certain neurotransmitter systems. While these applications are still in early stages, they highlight the broad therapeutic potential inherent in compounds like doxazosin mesylate.

In conclusion, doxazosin mesylate (CAS No. 77883-43-3) is a multifaceted pharmaceutical agent with established uses in treating hypertension and BPH while holding promise for future therapeutic applications through ongoing research efforts within medicinal chemistry communities worldwide.

77883-43-3 (Doxazosin mesylate) Related Products

Recommended suppliers
Suzhou Senfeida Chemical Co., Ltd
(CAS:77883-43-3)Doxazosin mesylate
sfd7522
Purity:99.9%
Quantity:200kg
Price ($):Inquiry
Email
Amadis Chemical Company Limited
(CAS:77883-43-3)Doxazosin mesylate
A839262
Purity:99%
Quantity:25g
Price ($):298.0
Email